Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

“Our third year of providing RSV protection marks a transformative era in infant health,” Thomas Triomphe, Sanofi’s vaccine chief, said in Monday’s release. “Backed by more than 40 real ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D.

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets. Paris-based Sanofi is the parent company of ...

Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional ...

S anofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sanofi successfully prices €1.5 billion bond issue. Paris, June 17, 2025- Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:.

18.3% of patients on Dupixent achieved sustained remission vs. 6.1% on placebo at 36 weeks. Median corticosteroid use was 2.8g with Dupixent vs. 4.1g with placebo in BP patients. From tariffs to ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...